Proactive Investors - Run By Investors For Investors

Alkermes Plc gets a boost as FDA approves its injectable schizophrenia drug

ARISTADA INITIO is expected to hit the market later this month
Needle
Alkermes shares are up nearly 7% in pre-market trade on the news

Alkermes Plc (NASDAQ:ALKS) reported a dose of good news, with today’s announcement that the US Food and Drug Administration has given the go-ahead and approved ARISTADA INITIO, its long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults.

ARISTADA INITIO (aripiprazole lauroxil), which is taken with a single 30mg dose of oral aripiprazole, is expected to hit the market this month.

“The approval of ARISTADA INITIO makes ARISTADA the first and only long-acting atypical antipsychotic that can be initiated on day one, representing an important addition to the treatment paradigm for the complex illness of schizophrenia,” said Dr. David Walling, chief executive and principal investigator of the Collaborative Neuroscience Network.

“For physicians and caregivers alike, the ARISTADA INITIO regimen provides a level of confidence that patients can walk out the door with up to two months of coverage with a proven medication in their system,” Walling added.

Schizophrenia is a chronic and disabling disorder, which involves hallucinations, delusions, depression and social withdrawal. As many as 2.4mln American adults have schizophrenia.

Alkermes shares climbed 6.85% to US$43.98 on the announcement of the drug’s approval.

View full ALKS profile View Profile

Alkermes Timeline

Related Articles

PT exercises
December 20 2018
The Californian company is a bet on an industry that is in need of transformation
cancer scans
July 05 2019
Here we take a closer look at Physiomics, the AIM company that owns a piece of software called Virtual Tumour that predicts the effects of drugs on cancers
pills
April 13 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use